Management of familial hyperparathyroidism syndromes

MEN1, MEN2, MEN4, HPT-Jaw tumour, Familial isolated hyperparathyroidism, FHH, and neonatal severe hyperparathyroidism

Eller Vainicher Cristina, Falchetti Alberto

Research output: Contribution to journalArticle

Abstract

While primary hyperparathyroidism (PHPT) generally represents a common endocrine disorder, being the more frequent cause of hypercalcemia in outpatients, familial forms of PHPT (FPHPT) account for no more than 2–5% of the overall PHPT. In the last decades, many technical progresses in both molecular and biochemical-radiological evaluation have been made, and substantial advancements in understanding these disorders have been reached. Differences both in the pathogenesis and clinical presentation exist among the various hyperparathyroid syndromic forms, and, since FPHPT is frequently associated to other endocrine, proliferative and/or functional disorders, as also non-endocrine tumours, with varying clinical spectrum of occurrence in each syndrome, its early clinically detection for appropriately preventing complications (i.e. kidney and bone disorders) is strictly advised. In this review, the clinical-biochemical features and diagnostic procedures of each FPHPT form will be summarized and a general overview on surgical and pharmacological approaches to FPHPT has been also considered.

Original languageEnglish
Pages (from-to)861-875
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume32
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint

Multiple Endocrine Neoplasia Type 1
Primary Hyperparathyroidism
Hyperparathyroidism
Jaw
Neoplasms
Hypercalcemia
Outpatients
Pharmacology
Kidney
Bone and Bones
Hyperparathyroidism 1
Hyperparathyroidism 3

Keywords

  • biochemical-clinical diagnosis of familial primary hyperparathyroidism
  • familial primary hyperparathyroidism
  • parathyroid tumours
  • pathogenesis of familial primary hyperparathyroidism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{373f9745edcf4095bc5fda8aae1cd7a3,
title = "Management of familial hyperparathyroidism syndromes: MEN1, MEN2, MEN4, HPT-Jaw tumour, Familial isolated hyperparathyroidism, FHH, and neonatal severe hyperparathyroidism",
abstract = "While primary hyperparathyroidism (PHPT) generally represents a common endocrine disorder, being the more frequent cause of hypercalcemia in outpatients, familial forms of PHPT (FPHPT) account for no more than 2–5{\%} of the overall PHPT. In the last decades, many technical progresses in both molecular and biochemical-radiological evaluation have been made, and substantial advancements in understanding these disorders have been reached. Differences both in the pathogenesis and clinical presentation exist among the various hyperparathyroid syndromic forms, and, since FPHPT is frequently associated to other endocrine, proliferative and/or functional disorders, as also non-endocrine tumours, with varying clinical spectrum of occurrence in each syndrome, its early clinically detection for appropriately preventing complications (i.e. kidney and bone disorders) is strictly advised. In this review, the clinical-biochemical features and diagnostic procedures of each FPHPT form will be summarized and a general overview on surgical and pharmacological approaches to FPHPT has been also considered.",
keywords = "biochemical-clinical diagnosis of familial primary hyperparathyroidism, familial primary hyperparathyroidism, parathyroid tumours, pathogenesis of familial primary hyperparathyroidism",
author = "Cristina, {Eller Vainicher} and Falchetti Alberto",
year = "2018",
doi = "10.1016/j.beem.2018.09.010",
language = "English",
volume = "32",
pages = "861--875",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Bailliere Tindall Ltd",
number = "6",

}

TY - JOUR

T1 - Management of familial hyperparathyroidism syndromes

T2 - MEN1, MEN2, MEN4, HPT-Jaw tumour, Familial isolated hyperparathyroidism, FHH, and neonatal severe hyperparathyroidism

AU - Cristina, Eller Vainicher

AU - Alberto, Falchetti

PY - 2018

Y1 - 2018

N2 - While primary hyperparathyroidism (PHPT) generally represents a common endocrine disorder, being the more frequent cause of hypercalcemia in outpatients, familial forms of PHPT (FPHPT) account for no more than 2–5% of the overall PHPT. In the last decades, many technical progresses in both molecular and biochemical-radiological evaluation have been made, and substantial advancements in understanding these disorders have been reached. Differences both in the pathogenesis and clinical presentation exist among the various hyperparathyroid syndromic forms, and, since FPHPT is frequently associated to other endocrine, proliferative and/or functional disorders, as also non-endocrine tumours, with varying clinical spectrum of occurrence in each syndrome, its early clinically detection for appropriately preventing complications (i.e. kidney and bone disorders) is strictly advised. In this review, the clinical-biochemical features and diagnostic procedures of each FPHPT form will be summarized and a general overview on surgical and pharmacological approaches to FPHPT has been also considered.

AB - While primary hyperparathyroidism (PHPT) generally represents a common endocrine disorder, being the more frequent cause of hypercalcemia in outpatients, familial forms of PHPT (FPHPT) account for no more than 2–5% of the overall PHPT. In the last decades, many technical progresses in both molecular and biochemical-radiological evaluation have been made, and substantial advancements in understanding these disorders have been reached. Differences both in the pathogenesis and clinical presentation exist among the various hyperparathyroid syndromic forms, and, since FPHPT is frequently associated to other endocrine, proliferative and/or functional disorders, as also non-endocrine tumours, with varying clinical spectrum of occurrence in each syndrome, its early clinically detection for appropriately preventing complications (i.e. kidney and bone disorders) is strictly advised. In this review, the clinical-biochemical features and diagnostic procedures of each FPHPT form will be summarized and a general overview on surgical and pharmacological approaches to FPHPT has been also considered.

KW - biochemical-clinical diagnosis of familial primary hyperparathyroidism

KW - familial primary hyperparathyroidism

KW - parathyroid tumours

KW - pathogenesis of familial primary hyperparathyroidism

UR - http://www.scopus.com/inward/record.url?scp=85054747574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054747574&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2018.09.010

DO - 10.1016/j.beem.2018.09.010

M3 - Article

VL - 32

SP - 861

EP - 875

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 6

ER -